<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-127382" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sacral Neuromodulation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Feloney</surname>
            <given-names>Michael P.</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stauss</surname>
            <given-names>Kari</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Feloney declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kari Stauss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-127382.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sacral neuromodulation is a well-established,&#x000a0;safe, effective, and minimally invasive advanced therapy for managing various lower urinary tract and bowel dysfunctions, including urinary and fecal incontinence, urgency, frequency, and retention.&#x000a0;Sacral neuromodulation is especially advantageous for patients who have not seen improvement with conservative treatments. The procedure involves implanting a neurostimulator that delivers electrical impulses to the sacral nerves, thereby effectively modulating neural pathways and restoring bladder and bowel function.&#x000a0;</p>
        <p>Sacral neuromodulation demonstrates notable effectiveness in addressing refractory urinary tract dysfunction and has proven efficacy in patients experiencing neurogenic bladder symptoms, including those associated with Parkinson disease. Furthermore, sacral neuromodulation is recommended for chronic fecal incontinence, providing patients with a minimally invasive option that holds significant promise for symptom improvement and an enhanced quality of life.&#x000a0;This activity offers clinicians a comprehensive understanding of sacral neuromodulation, encompassing patient selection, pre- and postoperative&#x000a0;management, surgical techniques, and programming optimization,&#x000a0;while also mastering evidence-based strategies for conducting lead placement procedures, addressing complications, and coordinating multidisciplinary care.&#x000a0;This activity enables clinicians to offer more effective and personalized treatment options for patients with complex lower urinary tract and bowel dysfunction by enhancing their competence in sacral neuromodulation, ultimately leading to improved patient outcomes and satisfaction.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify suitable candidates for sacral neuromodulation therapy based on clinical presentations,&#x000a0;history, symptoms, and responsiveness to conservative treatments.</p></list-item><list-item><p>Implement lead placement procedures for sacral neuromodulation with precision and adherence to best practices.</p></list-item><list-item><p>Select appropriate programming parameters for sacral neuromodulation devices based on individual patient needs and responses.</p></list-item><list-item><p>Collaborate with other healthcare professionals to coordinate comprehensive care plans and devise postoperative management strategies for patients undergoing sacral neuromodulation.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=127382&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=127382">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-127382.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sacral neuromodulation is a well-established, safe, effective, and minimally invasive advanced therapy used to treat various lower urinary tract and bowel dysfunctions, including urinary and fecal incontinence and urinary urgency, frequency, and retention in the United States.&#x000a0;Sacral neuromodulation is especially advantageous for patients who have not seen improvement with conservative treatments and&#x000a0;have not responded to behavioral and pharmacological treatments. In addition, sacral neuromodulation is indicated for chronic constipation in Canada and Europe.<xref ref-type="bibr" rid="article-127382.r1">[1]</xref></p>
        <p>Sacral neuromodulation therapy, developed in 1982 by Tanagho and Schmidt, gained approval from the United States Food and Drug Administration (FDA) in 1997.<xref ref-type="bibr" rid="article-127382.r2">[2]</xref><xref ref-type="bibr" rid="article-127382.r3">[3]</xref>&#x000a0;More than 300,000 patients have been treated with&#x000a0;sacral neuromodulation implants worldwide.<xref ref-type="bibr" rid="article-127382.r4">[4]</xref>&#x000a0;Reviews suggest that between 16%&#x000a0;and 29% of the population (with some estimates as high as 75%) experience some level of overactive bladder, including symptoms of urinary incontinence, urgency, or frequency.<xref ref-type="bibr" rid="article-127382.r5">[5]</xref><xref ref-type="bibr" rid="article-127382.r6">[6]</xref>&#x000a0;Moreover, an estimated 25% to 40% of patients experiencing overactive bladder do not achieve satisfactory results after first- and second-line therapies (behavioral modifications and pharmacotherapy, respectively).<xref ref-type="bibr" rid="article-127382.r7">[7]</xref>&#x000a0;These patients have a refractory overactive bladder and may be eligible for sacral neuromodulation therapy.</p>
        <p>Sacral neuromodulation has demonstrated significant clinical efficacy, particularly in otherwise intractable cases. In a study by Siegel et al, which evaluated 340 patients using sacral neuromodulation for 36 months, the success rate for overactive bladder was 83% among those who underwent sacral neuromodulation implantation (95% CI). Furthermore, 80% of patients reported improvement in all urinary symptoms.<xref ref-type="bibr" rid="article-127382.r8">[8]</xref><xref ref-type="bibr" rid="article-127382.r9">[9]</xref></p>
        <p>Although the mechanism of action of sacral neuromodulation remains not fully understood, the therapy appears to modulate spinal cord reflexes and brain involvement via afferent signaling rather than direct motor stimulation of the detrusor or urethral sphincter muscles.<xref ref-type="bibr" rid="article-127382.r10">[10]</xref>&#x000a0;The&#x000a0;prevailing theory suggests that sacral neuromodulation blocks or otherwise interferes with the afferent input to the sacral spinal cord, thereby inhibiting detrusor overactivity and resulting in clinical relief of urinary frequency and urgency.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref></p>
      </sec>
      <sec id="article-127382.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>
<bold>Lower Urinary Tract</bold>
</p>
        <p>The lower urinary tract performs 2 primary functions&#x02014;storing and voiding urine, both regulated by a complex neuronal control system. Disruptions to this system can result in neurogenic bladder, characterized by voiding dysfunction. Notably, significant voiding dysfunction can manifest even without identifiable neurological lesions.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref> Symptoms may include difficult voiding, postvoid complications, and bladder storage issues such as frequency, urgency, urge incontinence, difficult urination, and incomplete emptying.<xref ref-type="bibr" rid="article-127382.r12">[12]</xref></p>
        <p>
<bold>Efferent Pathways of Lower Urinary Tract</bold>
</p>
        <p>Parasympathetic preganglionic fibers, originating from the sacral spinal cord (S2-S4), are pivotal in initiating micturition. They stimulate contraction of the bladder detrusor muscle while inhibiting the urethral sphincter. Postganglionic fibers release acetylcholine and synapse with M2 and M3 receptors in the bladder. M2 receptors, prevalent in the detrusor, primarily mediate bladder smooth muscle contraction. In contrast, parasympathetic innervation to the urethral smooth muscle, controlling the internal urinary sphincter, is inhibitory and mediated by nitric oxide.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref> Thus, anticholinergics such as oxybutynin and tolterodine, which inhibit M2 and M3 receptors, can serve as pharmacotherapy for overactive bladder, urgency, frequency, and urge incontinence.<xref ref-type="bibr" rid="article-127382.r5">[5]</xref>&#x000a0;Conversely, cholinergic agonists such as bethanechol can be utilized for nonobstructive urinary retention caused by detrusor hypoactivity.<xref ref-type="bibr" rid="article-127382.r13">[13]</xref>&#x000a0;</p>
        <p>Sympathetic preganglionic fibers originate from the intermediolateral nuclei in the thoracolumbar region of the spinal cord. These fibers traverse the hypogastric nerve and either synapse in the inferior mesenteric ganglion or join the pelvic nerves via the paravertebral chain. The activation of sympathetic pathways inhibits micturition, resulting in detrusor relaxation and constriction of the urethral sphincter.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref> Postganglionic sympathetic axons synapse with &#x003b2;2 and &#x003b2;3 receptors in the detrusor wall and &#x003b1;1 receptors of the urethral sphincter.<xref ref-type="bibr" rid="article-127382.r14">[14]</xref>&#x000a0;Medical treatments utilizing &#x003b2;3 sympathetic agonists, such as mirabegron and vibegron, effectively address symptoms of urinary urgency, frequency, overactivity, and urge incontinence without inducing anticholinergic adverse effects.<xref ref-type="bibr" rid="article-127382.r5">[5]</xref><xref ref-type="bibr" rid="article-127382.r15">[15]</xref><xref ref-type="bibr" rid="article-127382.r16">[16]</xref></p>
        <p>Somatic efferent fibers originate from the Onuf nucleus at S2-S4 and travel as the pudendal nerve to the external urinary sphincter, releasing acetylcholine upon activation. The sphincter is composed of skeletal muscle and contains cholinergic receptors. Acetylcholine stimulation induces sphincter contraction, mechanically and reflexively inhibiting micturition. Moreover, the pudendal and hypogastric nerves transmit sensory input from the bladder neck, urethra, and perineum to the brain and spinal cord.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref></p>
        <p>The guarding reflex prevents accidental leakage caused by sudden or involuntary increases in bladder pressure, commonly known as stress incontinence. When bladder pressure abruptly rises, such as during coughing, sneezing, standing, or laughing, excitatory afferent fibers stimulate the Onuf nucleus to activate somatic efferent fibers, leading to contraction of the external urinary sphincter.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref></p>
        <p>
<bold>Afferent Pathways of Lower Urinary Tract</bold>
</p>
        <p>Sensory signals from the bladder travel to the dorsal horn of the spinal cord via the pelvic and hypogastric nerves. Afferent fibers transmit electrical impulses from tension receptors and nociceptors in the bladder wall. Typically, myelinated A&#x003b4; fibers facilitate bladder distension. However, unmyelinated C fibers may become hyperactive during inflammation and neurogenic conditions.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref></p>
        <p>Sensory signals from the urethra travel to the spinal cord via the pelvic and pudendal nerves. Urethral afferent nerves are activated by the passage of urine through the urethra, enhancing the parasympathetic input to the bladder. This causes a positive feedback mechanism to ensure complete bladder emptying.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref></p>
        <p>Sensory input from the lower urinary tract reaches the pontine micturition center in the brainstem, where it interacts with the frontal micturition inhibiting center in the cerebrum. This process suppresses micturition until voluntary voiding is initiated in the cerebrum, which inhibits the micturition center.<xref ref-type="bibr" rid="article-127382.r17">[17]</xref></p>
        <p>
<bold>Rectum and Anal Sphincters</bold>
</p>
        <p>The rectum serves as the connection between the gastrointestinal tract and the anus, facilitating both stool storage and passage. Defecation involves a combination of voluntary and involuntary muscle actions, with sensory input mediated by pelvic nerves.<xref ref-type="bibr" rid="article-127382.r18">[18]</xref> Neurogenic disruptions in the lower gastrointestinal tract can lead to symptoms such as diarrhea, constipation, and fecal incontinence, with obstetric anal trauma being 1 of the most prevalent and well-recognized contributing factors for fecal incontinence.<xref ref-type="bibr" rid="article-127382.r19">[19]</xref> A recent study involving 221 patients with fecal incontinence revealed that 80% of those who underwent implantation experienced a lasting improvement of at least 50% in their leakage issues.<xref ref-type="bibr" rid="article-127382.r20">[20]</xref></p>
        <p>
<bold>Defecation Reflexes</bold>
</p>
        <p>Rectoanal sampling, also known as the rectoanal inhibitory reflex, is a cyclic process that recurs approximately every 8 to 10 minutes when rectal contents stimulate the anal sensory mucosa.<xref ref-type="bibr" rid="article-127382.r21">[21]</xref> The relaxation of the internal anal sphincter during this reflex varies depending on the degree of rectal distension.<xref ref-type="bibr" rid="article-127382.r22">[22]</xref> As&#x000a0;rectal contents move into the upper anal canal, sensory discrimination between solid, liquid, or gaseous materials occurs.<xref ref-type="bibr" rid="article-127382.r23">[23]</xref></p>
        <p>Defecation initiates upon reaching a critical threshold of rectal distension, signaling the cerebral cortex.<xref ref-type="bibr" rid="article-127382.r24">[24]</xref> Sensory stimulation and distension within the rectum trigger a parasympathetic-mediated reflex, resulting in relaxation of the anal sphincters and pelvic floor, thereby facilitating stool passage into the lower rectum and anal canal.<xref ref-type="bibr" rid="article-127382.r25">[25]</xref>&#x000a0;As the final stool bolus traverses the anal canal, the external sphincter reflexively initiates closure in response to the relief of rectal distension.<xref ref-type="bibr" rid="article-127382.r26">[26]</xref></p>
        <p>The somatic nervous system controls the external anal sphincter via the pudendal nerve.<xref ref-type="bibr" rid="article-127382.r27">[27]</xref>&#x000a0;Deferment of defecation occurs through contraction of the external anal sphincter, resisting the increase in rectal pressure sufficiently to enable muscle adaptation, leading to a reduction in rectal pressure and the feeling of urgency.<xref ref-type="bibr" rid="article-127382.r28">[28]</xref></p>
        <p>
<bold>Mechanism of Sacral Neuromodulation</bold>
</p>
        <p>Although a complete understanding of the mechanisms of sacral neuromodulation remains elusive due to its likely multifaceted nature, several theories have been proposed, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>In neurogenic bladder conditions such as multiple sclerosis, meningomyelocele, and spinal cord injury, afferent C fibers can become more active due to neurologic and inflammatory disorders. C fibers can respond to bladder distension and activate voiding reflexes.<xref ref-type="bibr" rid="article-127382.r29">[29]</xref>&#x000a0;Sacral neuromodulation is thought to block C fiber activity, inhibiting irregular voiding responses.<xref ref-type="bibr" rid="article-127382.r30">[30]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As previously described, the urethral guarding reflex serves as a protective mechanism against stress urinary incontinence. Sacral neuromodulation is believed to inhibit the guarding reflex and induce voiding in patients with urinary retention.<xref ref-type="bibr" rid="article-127382.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sacral neuromodulation appears to stimulate the relaxation of pelvic floor muscles and the urethra, which helps initiate micturition in patients with impaired bladder pressure, retention, and incomplete emptying.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref><xref ref-type="bibr" rid="article-127382.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A possible central mechanism has also been suggested. Patients with refractory overactive bladder who have been successfully treated with&#x000a0;sacral neuromodulation have exhibited significant activation of Brodmann area 9 (specifically the left dorsolateral prefrontal cortex) following sacral neuromodulation treatment.<xref ref-type="bibr" rid="article-127382.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Additional mechanisms are proposed for urinary urgency and frequency. When stimulated, the&#x000a0;afferent portion of the pudendal nerve may inhibit bladder afferent pathways. Similarly, inhibiting preganglionic neurons in efferent bladder pathways may also decrease incontinence. The sustained ability to voluntarily void throughout therapy indicates that inhibition of the micturition reflex is a component of the sacral neuromodulation mechanism.<xref ref-type="bibr" rid="article-127382.r11">[11]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The precise mechanisms underlying how sacral neuromodulation aids in controlling fecal incontinence remain poorly understood. Most research suggests that placing the sacral neuromodulation lead in the S3 region stimulates afferent fibers from the anal sphincter, rectum, and pelvic floor. This stimulation of afferents decreases the activation of C fibers during rectal filling, thus blocking inputs from the rectum to the pontine center.<xref ref-type="bibr" rid="article-127382.r34">[34]</xref> Additionally, sacral neuromodulation may activate somatic afferent fibers, leading to the inhibition of colonic activity and the enhancement of internal anal sphincter tone through a somatovisceral reflex mechanism.<xref ref-type="bibr" rid="article-127382.r35">[35]</xref><xref ref-type="bibr" rid="article-127382.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-127382.s4" sec-type="Indications">
        <title>Indications</title>
        <p>Sacral neuromodulation is indicated for refractory urinary tract dysfunction, including symptoms of nonobstructive urinary retention, urgency, frequency, and urge incontinence. Sacral neuromodulation has shown efficacy in Parkinson patients with neurogenic bladder symptoms, who are often refractory to treatment. In a recent study, 82% of Parkinson's patients with neurogenic bladders responded positively to sacral neuromodulation therapy, with many discontinuing their oral medications for overactive bladder.<xref ref-type="bibr" rid="article-127382.r37">[37]</xref>&#x000a0;Additionally,&#x000a0;sacral neuromodulation is indicated for chronic fecal incontinence.<xref ref-type="bibr" rid="article-127382.r38">[38]</xref><xref ref-type="bibr" rid="article-127382.r39">[39]</xref><xref ref-type="bibr" rid="article-127382.r40">[40]</xref><xref ref-type="bibr" rid="article-127382.r41">[41]</xref></p>
        <p>
<bold>Patient Selection</bold>
</p>
        <p>Patients eligible for&#x000a0;sacral neuromodulation therapy for urinary incontinence must have refractory nonobstructive urinary retention, urgency, urge incontinence, or severe frequency that have failed to respond to behavioral modifications and pharmacotherapy&#x000a0;despite undergoing more than one medical therapy for a duration of 8 to 12 weeks.<xref ref-type="bibr" rid="article-127382.r42">[42]</xref>&#x000a0;Individuals undergoing sacral neuromodulation therapy are encouraged to maintain a voiding diary to track urinary and fecal symptoms and establish a baseline. This diary should be consistently updated throughout the clinical trial period to evaluate any improvement, with a reduction in symptoms of 50% or more considered successful.<xref ref-type="bibr" rid="article-127382.r43">[43]</xref></p>
        <p>Sacral neuromodulation is not recommended by the American Urological Association Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction (2021) for patients with spina bifida or spinal cord injuries due to the significant variability in bladder function and progression.<xref ref-type="bibr" rid="article-127382.r44">[44]</xref> However, sacral neuromodulation may be considered for patients with other types of neurogenic bladder. This includes cases causing urgency, frequency, or urge incontinence that are not effectively managed with more conservative measures.<xref ref-type="bibr" rid="article-127382.r44">[44]</xref></p>
      </sec>
      <sec id="article-127382.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Sacral neuromodulation is contraindicated in patients with&#x000a0;urinary obstruction or current pelvic infection. Additionally, patients with severe or rapidly progressive neurologic disease are relatively contraindicated from undergoing sacral neuromodulation therapy.<xref ref-type="bibr" rid="article-127382.r45">[45]</xref></p>
        <p>Additional contraindications for sacral neuromodulation therapy include shortwave diathermy, microwave diathermy, therapeutic ultrasound, mechanical obstruction, and the patient's inability to operate the programmer.<xref ref-type="bibr" rid="article-127382.r46">[46]</xref>&#x000a0;In earlier iterations of sacral neuromodulation systems, not all devices were fully compatible with magnetic resonance imaging (MRI). As of 2020, all new implants are compatible with full-body MRIs. However, some implants manufactured before the fall of 2019 lack full MRI compatibility, necessitating limitations on MRI evaluations and imaging to just the head and neck for these patients. A comprehensive listing of MRI-compatible sacral neuromodulation devices has recently been published.<xref ref-type="bibr" rid="article-127382.r4">[4]</xref><xref ref-type="bibr" rid="article-127382.r47">[47]</xref></p>
        <p>Although age and comorbidities are not considered contraindications, there is evidence suggesting that patients aged 55 or older with 3 or more chronic comorbid conditions may experience reduced success rates in improving their voiding symptoms with sacral neuromodulation.<xref ref-type="bibr" rid="article-127382.r48">[48]</xref></p>
      </sec>
      <sec id="article-127382.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>Essential equipment for sacral neuromodulation procedures&#x000a0;includes a sacral neuromodulation kit containing the tined lead, foramen needle, and internal pulse generator (IPG). Surgical supplies such as sterile surgical drapes and a basic surgical instrument tray are necessary. Furthermore, a C-arm fluoroscopic unit is essential for precise lead placement during the procedure.</p>
      </sec>
      <sec id="article-127382.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>During the peripheral nerve evaluation stage (step 1), the procedure requires the presence of a surgeon, a nurse, and an x-ray technician. Subsequently, during the implant stage (step 2), the procedure necessitates the participation of a surgeon, nurse, scrub technician, and either an anesthesiologist or a nurse anesthetist. Optionally, a representative from the sacral neuromodulation manufacturer may be present during the procedure to prepare and test the product for implantation, interrogate the IPG, and verify the leads for a motor response.</p>
      </sec>
      <sec id="article-127382.s8" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>
<bold>Evaluation</bold>
</p>
        <p>The evaluation stage allows for a trial of therapy before opting for the complete implant. This procedure is conducted under local anesthesia to ensure sensory innervation is an important indicator of lead placement. The patient is positioned prone, and a C-arm fluoroscopy is positioned accordingly. General landmarks of the sacrum are then identified, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>The base of the sacrum, which is located by following the iliac crest medially.</p>
          </list-item>
          <list-item>
            <p>The apex of the sacrum, which is located at the sacrococcygeal articulation.</p>
          </list-item>
          <list-item>
            <p>The median sacral crest, which is located along the sacrum midline between the sacral foramina<xref ref-type="bibr" rid="article-127382.r46">[46]</xref></p>
          </list-item>
        </list>
        <p>During sacral neuromodulation lead placement, a foramen needle is angled at 60&#x000b0; and inserted into the S3 foramen. The desired motor response includes dorsiflexion of the great toe and contraction in the perineum and anus, known as the bellows reflex. Sensory responses may include fluttering or vibration sensations or pulling sensations in the scrotum, vagina, perineum, or inner gluteal fold. In addition, the clinician must be familiar with S2 and S4 nerve root responses, as they may not result in optimal therapy outcomes. Stimulation of the S2 root typically induces pinching of the anal sphincter, plantar flexion, and lateral foot rotation, accompanied by sensations in the leg and buttock area. In contrast, stimulation of the S4 root triggers the bellows reflex without lower extremity movement and elicits a pulling sensation around the perineum.<xref ref-type="bibr" rid="article-127382.r49">[49]</xref></p>
        <p>After removing the stylet from the foramen needle, it is substituted with a directional guide. While maintaining the guide in position, the foramen needle is withdrawn. A small transverse incision is made at the skin entry point to facilitate the introducer's passage into the S3 foramen. Once advanced, the directional guide is removed, leaving the introducer sheath in place. Subsequently, the tined lead is inserted so that electrodes 2 and 3 straddle the sacral foramen, with electrode 3 positioned as the most proximal. Electrodes 0 and 1 are situated anterior to the bony sacrum, with electrode 0 being the most distal.<xref ref-type="bibr" rid="article-127382.r50">[50]</xref> Recent studies recommend inserting the tined lead to occupy the most superior and medial space in the foramen, resulting in electrode 3 being positioned just beyond the foramen rather than straddling it.<xref ref-type="bibr" rid="article-127382.r51">[51]</xref> Finally, the lead stylet and introducer sheath are withdrawn to allow the tines to deploy and secure the lead in place.</p>
        <p>After testing all electrodes, motor and sensory responses are ideally observed at 2 mA or less. Subsequently, the lead is tunneled through a small gluteal incision over the iliac crest and connected to a percutaneous extension cable passed subcutaneously to the contralateral side below the hip. The percutaneous extension is then plugged into the external neurostimulator for the trial period.<xref ref-type="bibr" rid="article-127382.r46">[46]</xref>&#x000a0;The trial for evaluating the tined lead lasts for 7 to 14 days. Stage 2, which involves either complete implantation or removal of the leads, must be scheduled separately and will depend on the trial results.<xref ref-type="bibr" rid="article-127382.r46">[46]</xref></p>
        <p>The precise placement of the tined lead during the procedure is crucial to ensure it follows the S3 root for optimal outcomes. Accurate identification of sacral landmarks is essential for success. Video guides can assist in learning and troubleshooting the lead placement process, thereby enhancing procedural precision and efficacy.<xref ref-type="bibr" rid="article-127382.r52">[52]</xref></p>
        <p>In select cases, computed tomography (CT) guidance&#x000a0;is an alternative to C-arm fluoroscopy for electrode placement.<xref ref-type="bibr" rid="article-127382.r53">[53]</xref>&#x000a0;Recent advancements include computer-assisted lead placement, which utilizes surgical navigation systems with electromagnetic tracking to precisely guide leads to the S3 nerve roots. These innovations facilitate optimal lead positioning, especially in challenging clinical scenarios, thereby enhancing procedural accuracy and efficacy.<xref ref-type="bibr" rid="article-127382.r54">[54]</xref></p>
        <p>Good prognostic indicators that suggest maximal success with sacral neuromodulation include optimal lead placement, ideal motor threshold levels, and the utilization of curved stylets.<xref ref-type="bibr" rid="article-127382.r55">[55]</xref>&#x000a0;Monopolar configurations are generally more effective and stimulate more motor nerve fibers at lower sensory thresholds, leading to greater therapeutic efficacy. Moreover, in addition to reprogramming, changing the polarity or the position of the cathode lead can significantly alter sensory and motor responses.<xref ref-type="bibr" rid="article-127382.r56">[56]</xref></p>
        <p>
<bold>Implant</bold>
</p>
        <p>Following a successful trial period demonstrating at least a 50% improvement in symptoms, the IPG is implanted. The&#x000a0;previous gluteal incision site is enlarged to accommodate the insertion of the IPG. The lead is then connected directly to the IPG at the neurostimulator head. Typically, the IPG is not sutured into the pocket to prevent the sensation of pulling or tugging, as dislocation of the IPG is rare.<xref ref-type="bibr" rid="article-127382.r46">[46]</xref> Optionally, an antimicrobial mesh pouch can be sutured into the pocket to stabilize the device and prevent infection.</p>
        <p>Commonly reported adverse events associated with sacral neuromodulation that necessitate revision include pain at the neurostimulator site (11.8% of patients with implants) and lead migration (7.9% of patients with implants).<xref ref-type="bibr" rid="article-127382.r57">[57]</xref></p>
        <p>Neurostimulators are equipped with preprogrammed factory settings for lower urinary tract disorders and fecal incontinence. These programs include specific parameters such as pulse width, frequency, active electrodes, and cycling pattern. Patients have the flexibility to switch between preset programs and adjust the device's amplitude settings. Various variables can be used to program the patient's IPG, necessitating collaboration between the patient and the medical team to fine-tune program parameters for optimal therapy.<xref ref-type="bibr" rid="article-127382.r58">[58]</xref>&#x000a0;During office visits, providers can customize all settings using a physician programmer to meet each patient's unique requirements. Regular yearly follow-up appointments post-implantation are recommended to ensure ongoing symptom management.</p>
        <p>The duration of treatment is directly related to the longevity of the implantable battery. Nonrechargeable implants typically last around 5 years on average.<xref ref-type="bibr" rid="article-127382.r59">[59]</xref>&#x000a0;By utilizing lower settings, the battery's lifespan can be extended. Recent technological advancements have introduced higher-capacity batteries in newer devices, allowing for wireless recharging and a lifespan of up to 15 years.<xref ref-type="bibr" rid="article-127382.r60">[60]</xref>&#x000a0;Additionally, there have been advancements in neuromodulation technology, including enhanced programming capabilities, single-stage outpatient implantation to reduce invasiveness, and the development of lower-cost implantable devices.<xref ref-type="bibr" rid="article-127382.r39">[39]</xref></p>
      </sec>
      <sec id="article-127382.s9" sec-type="Complications">
        <title>Complications</title>
        <p>The most severe complications of sacral neuromodulation are typically associated with lead migration, implant site pain, or infection.<xref ref-type="bibr" rid="article-127382.r61">[61]</xref>&#x000a0;These issues can significantly impact the effectiveness of treatment and may require further intervention or device removal.</p>
        <p>The most common concern is that the patient no longer benefits from the therapy. Initially, the neurostimulator should be interrogated to confirm it is turned on. Subsequently, the resistances of the electrodes should be checked to rule out an open or short circuit. Assuming the device is activated, and there is no short circuit, adjustments to the programs should be made. The program encodes the active electrodes, including stimulation frequency, amplitude, and pulse width.<xref ref-type="bibr" rid="article-127382.r61">[61]</xref> Additionally, adjusting the pulse width, alongside standard programming changes, can assist in pain relief and addressing efficacy issues.<xref ref-type="bibr" rid="article-127382.r62">[62]</xref></p>
        <p>Lead migration or improper placement is possible and can be identified with an x-ray. However, lead revision surgery should be considered only as a last resort.<xref ref-type="bibr" rid="article-127382.r52">[52]</xref> Before proceeding with surgery, it is crucial to review the issue with the manufacturing representative of the device and troubleshoot the flow process to explore alternative solutions.</p>
        <p>Bilateral sacral&#x000a0;electrical pudendal nerve stimulation has been successfully used in patients who, despite initial success, eventually fail standard sacral neuromodulation.<xref ref-type="bibr" rid="article-127382.r63">[63]</xref><xref ref-type="bibr" rid="article-127382.r64">[64]</xref><xref ref-type="bibr" rid="article-127382.r65">[65]</xref></p>
      </sec>
      <sec id="article-127382.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Combination Therapy</bold>
</p>
        <p>Tang et al conducted a study on women with overactive bladders treated with a combination of sacral neuromodulation and tolterodine&#x02014;an M2 and M3 antimuscarinic agent. After 3 months, the combination therapy demonstrated significant superiority over tolterodine alone, showing key improvements in various bladder parameters such as daily average single voided volume, daily maximum single volume of urination, first desire to void, and maximum cystometric capacity, indicating the bladder's tolerance volume before experiencing a strong, uncontrollable urge to urinate.<xref ref-type="bibr" rid="article-127382.r66">[66]</xref></p>
        <p>
<bold>Alternate Treatments</bold>
</p>
        <p><bold>Percutaneous tibial nerve stimulation:&#x000a0;</bold>Percutaneous&#x000a0;tibial&#x000a0;nerve&#x000a0;stimulation (PTNS) is an alternative neuromodulation therapy for intractable overactive bladder. This procedure targets the tibial nerve by gently stimulating it with a needle connected to a low-voltage stimulator near the medial malleolus in the foot. This stimulation indirectly influences the sacral nerves responsible for bladder function. Patients typically experience sensations such as "tingling" or "pulsing" in the foot or ankle during treatment, which is generally painless.</p>
        <p>Treatment sessions last for 30 minutes and are conducted weekly. Although some patients may notice symptomatic improvement as early as the second session, many require multiple treatments before experiencing significant benefits. Patients are advised to complete the full 12-week regimen initially, followed by clinical evaluation. Intermittent additional treatments may be needed for long-term symptomatic relief.</p>
        <p>PTNS can significantly improve urinary frequency, urgency, urge incontinence, and nocturia, benefiting 60% to 80% of patients, according to research.<xref ref-type="bibr" rid="article-127382.r67">[67]</xref>&#x000a0;Unlike anticholinergics or sacral neuromodulation, PTNS provides a carryover effect of continued symptom improvement even when the nerve is not actively stimulated.<xref ref-type="bibr" rid="article-127382.r68">[68]</xref> However, its limitations include the necessity for patients to be present in a clinical office for therapy sessions and commit to a full 12-week therapeutic trial.</p>
        <p>Although PTNS and sacral neuromodulation are generally well-tolerated, PTNS may entail fewer adverse effects and is notably less invasive than sacral neuromodulation. However, PTNS lacks the long-term testing that sacral neuromodulation has undergone.<xref ref-type="bibr" rid="article-127382.r69">[69]</xref>&#x000a0;Therefore, the choice between the 2 is primarily based on equipment availability and patient preference regarding clinic proximity and surgical tolerance.<xref ref-type="bibr" rid="article-127382.r70">[70]</xref> Despite its effectiveness in addressing fecal incontinence in other countries, PTNS lacks FDA approval for this indication in the United States.<xref ref-type="bibr" rid="article-127382.r20">[20]</xref><xref ref-type="bibr" rid="article-127382.r41">[41]</xref></p>
        <p>A wearable closed-loop transcutaneous tibial neuromodulation system has demonstrated efficacy, significantly reducing urinary frequency, urgency, and incontinence episodes over 12 weeks.<xref ref-type="bibr" rid="article-127382.r71">[71]</xref> The&#x000a0;response of this system remains durable up to 1 year of follow-up, and the device has received FDA approval.<xref ref-type="bibr" rid="article-127382.r71">[71]</xref> Patients demonstrate increased compliance and satisfaction compared to alternative therapy delivery methods. Another wearable tibial nerve neuromodulation device utilizing an ankle strap and an implantable electrode has shown similar efficacy.</p>
        <p><bold>Chemical denervation of the detrusor using the onabotulinum A toxin:&#x000a0;</bold>The FDA has approved botulinum toxin for therapeutic use.<xref ref-type="bibr" rid="article-127382.r72">[72]</xref>&#x000a0;Botulinum toxin injections can effectively manage overactive bladder and urinary urge incontinence, with results typically lasting 6 to 12 months, after which further injections can be administered.<xref ref-type="bibr" rid="article-127382.r73">[73]</xref>&#x000a0;Disadvantages of this treatment modality include possible urinary tract infections and urinary retention, affecting 5% to 15% of patients.<xref ref-type="bibr" rid="article-127382.r74">[74]</xref>&#x000a0;</p>
        <p>A recent cost-effectiveness comparison between sacral neuromodulation and onabotulinum A toxin was published for managing refractory overactive bladder issues.<xref ref-type="bibr" rid="article-127382.r75">[75]</xref>&#x000a0;The study examined various healthcare systems across&#x000a0;5 countries over&#x000a0;5- and 10-year periods. However, industry-sponsored studies, prevalent in the available literature, may influence outcomes. Although overall costs are similar, botulinum toxin seemed more cost-effective in the short term, while longer-term studies favor sacral neuromodulation.<xref ref-type="bibr" rid="article-127382.r75">[75]</xref>&#x000a0;</p>
        <p>
<bold>Pelvic Pain</bold>
</p>
        <p>Several studies suggest sacral neuromodulation's efficacy in improving pelvic pain, including interstitial cystitis. In a study by Siegel et al, 9 out of 10 patients with interstitial cystitis experienced reduced pain after sacral neuromodulation at 19 months of follow-up.<xref ref-type="bibr" rid="article-127382.r76">[76]</xref> T Pain levels decreased from an average of 9.7 to 4.4 on a scale of 0 to 10, with a decreasing trend in hours of pain.<xref ref-type="bibr" rid="article-127382.r76">[76]</xref>&#x000a0;However, sacral neuromodulation for interstitial cystitis lacks FDA approval, supported only by grade C evidence.<xref ref-type="bibr" rid="article-127382.r77">[77]</xref></p>
        <p>While the precise mechanisms of action of sacral neuromodulation for pelvic pain still need to be elucidated, most research supports the theory of afferent signaling modulation to achieve symptomatic improvement. Several distinct mechanisms for symptom relief seem to exist, and therapy likely functions differently for each clinical indication.</p>
        <p>
<bold>Future Use</bold>
</p>
        <p>Some patients with spinal cord injuries appear to have benefitted from the early use of sacral neuromodulation in preventing functional deterioration of the bladder. Detrusor overactivity and incontinence were prevented while bowel function, erectile activity, and a normal bladder capacity were maintained.<xref ref-type="bibr" rid="article-127382.r78">[78]</xref><xref ref-type="bibr" rid="article-127382.r79">[79]</xref><xref ref-type="bibr" rid="article-127382.r80">[80]</xref>&#x000a0;However, despite these promising outcomes, the early use of sacral neuromodulation to alter the course of spinal cord injury and preserve bladder function is still considered investigational.<xref ref-type="bibr" rid="article-127382.r81">[81]</xref>&#x000a0;</p>
        <p><bold>Summary</bold>&#x000a0;</p>
        <p>Sacral neuromodulation offers a reasonable, safe, effective, and reversible alternative for refractory overactive bladder, nonobstructive urinary retention, and fecal incontinence.<xref ref-type="bibr" rid="article-127382.r55">[55]</xref></p>
      </sec>
      <sec id="article-127382.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective care in sacral neuromodulation requires a collaborative effort among healthcare professionals to optimize patient-centered outcomes, safety, and team performance. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare team members contribute distinct skills and strategies to enhance patient care. Physicians and advanced practitioners utilize their expertise in patient assessment, diagnosis, and treatment planning to ensure sacral neuromodulation is appropriately indicated and executed. Nurses play a vital role in patient education, pre- and postoperative care, and ongoing support, fostering patient engagement and adherence.</p>
        <p>Pharmacists contribute by ensuring appropriate medication management, addressing drug interactions, and providing patient counseling. Effective interprofessional communication among healthcare team members ensures seamless care coordination, facilitates shared decision-making, and mitigates errors. By fostering a patient-centered approach and promoting collaboration among team members, healthcare professionals can optimize sacral neuromodulation outcomes, improve patient satisfaction, and elevate overall team performance in delivering high-quality care.</p>
      </sec>
      <sec id="article-127382.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=127382&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=127382">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/127382/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=127382">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-127382.s13">
        <title>References</title>
        <ref id="article-127382.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>O'Connell</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Lehur</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Matzel</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Laurberg</surname>
                <given-names>S</given-names>
              </name>
              <collab>European SNS Bowel Study Group</collab>
            </person-group>
            <article-title>Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement.</article-title>
            <source>Colorectal Dis</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>O74</fpage>
            <page-range>O74-87</page-range>
            <pub-id pub-id-type="pmid">25603960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanagho</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Bladder pacemaker: scientific basis and clinical future.</article-title>
            <source>Urology</source>
            <year>1982</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>614</fpage>
            <page-range>614-9</page-range>
            <pub-id pub-id-type="pmid">7179629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hetzer</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Fifteen years of sacral nerve stimulation: from an open procedure to a minimally invasive technique.</article-title>
            <source>Colorectal Dis</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>13 Suppl 2</volume>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">21284794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Wachter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Elterman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kennelly</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lehur</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Matzel</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Engelberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van Kerrebroeck</surname>
                <given-names>PEV</given-names>
              </name>
            </person-group>
            <article-title>New Technologies and Applications in Sacral Neuromodulation: An Update.</article-title>
            <source>Adv Ther</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>637</fpage>
            <page-range>637-643</page-range>
            <pub-id pub-id-type="pmid">31875299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Iglesia</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Overactive Bladder.</article-title>
            <source>Obstet Gynecol Clin North Am</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-68</page-range>
            <pub-id pub-id-type="pmid">26880508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rashid</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Ockrim</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Male incontinence: onabotulinum toxin A and sacral nerve stimulation.</article-title>
            <source>Curr Opin Urol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>545</fpage>
            <page-range>545-51</page-range>
            <pub-id pub-id-type="pmid">24080810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wein</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of the overactive bladder.</article-title>
            <source>Urology</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>5 Suppl 2</issue>
            <fpage>20</fpage>
            <page-range>20-7</page-range>
            <pub-id pub-id-type="pmid">14662403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noblett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mangel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griebling</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Comiter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Culkin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zylstra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>224</fpage>
            <page-range>224-30</page-range>
            <pub-id pub-id-type="pmid">24415559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noblett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mangel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griebling</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Comiter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Culkin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zylstra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Thiery</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation.</article-title>
            <source>Urology</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>94</volume>
            <fpage>57</fpage>
            <page-range>57-63</page-range>
            <pub-id pub-id-type="pmid">27131966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kessler</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation for urinary retention.</article-title>
            <source>Nat Clin Pract Urol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>657</fpage>
            <page-range>657-66</page-range>
            <pub-id pub-id-type="pmid">19002127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elkelini</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Abuzgaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hassouna</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of sacral neuromodulation.</article-title>
            <source>Int Urogynecol J</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>21 Suppl 2</volume>
            <fpage>S439</fpage>
            <page-range>S439-46</page-range>
            <pub-id pub-id-type="pmid">20972548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapple</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Wein</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dmochowski</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Giuliano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>McVary</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Lower urinary tract symptoms revisited: a broader clinical perspective.</article-title>
            <source>Eur Urol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>563</fpage>
            <page-range>563-9</page-range>
            <pub-id pub-id-type="pmid">18423969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaitonde</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Zimmern</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Bethanechol: Is it still being prescribed for bladder dysfunction in women?</article-title>
            <source>Int J Clin Pract</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>8</issue>
            <fpage>e13248</fpage>
            <pub-id pub-id-type="pmid">30112787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michel</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vrydag</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.</article-title>
            <source>Br J Pharmacol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>147 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>S88</fpage>
            <page-range>S88-119</page-range>
            <pub-id pub-id-type="pmid">16465187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tachikawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kyoda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fukuta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Masumori</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01.</article-title>
            <source>Low Urin Tract Symptoms</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-116</page-range>
            <pub-id pub-id-type="pmid">34713579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frankel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Staskin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Varano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kennelly</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jankowich</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Haag-Molkenteller</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2022</year>
            <volume>18</volume>
            <fpage>171</fpage>
            <page-range>171-182</page-range>
            <pub-id pub-id-type="pmid">35264853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fowler</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Groat</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>The neural control of micturition.</article-title>
            <source>Nat Rev Neurosci</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>453</fpage>
            <page-range>453-66</page-range>
            <pub-id pub-id-type="pmid">18490916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bajwa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Emmanuel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The physiology of continence and evacuation.</article-title>
            <source>Best Pract Res Clin Gastroenterol</source>
            <year>2009</year>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>477</fpage>
            <page-range>477-85</page-range>
            <pub-id pub-id-type="pmid">19647684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sultan</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kamm</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bartram</surname>
                <given-names>CI</given-names>
              </name>
            </person-group>
            <article-title>Anal-sphincter disruption during vaginal delivery.</article-title>
            <source>N Engl J Med</source>
            <year>1993</year>
            <month>Dec</month>
            <day>23</day>
            <volume>329</volume>
            <issue>26</issue>
            <fpage>1905</fpage>
            <page-range>1905-11</page-range>
            <pub-id pub-id-type="pmid">8247054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meurette</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Siproudhis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leroi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Damon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Urs Josef Keller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Faucheron</surname>
                <given-names>JL</given-names>
              </name>
              <collab>French Faecal Registry Study Group</collab>
            </person-group>
            <article-title>Sacral neuromodulation with the InterStim&#x02122; system for faecal incontinence: results from a prospective French multicentre observational study.</article-title>
            <source>Colorectal Dis</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>1463</fpage>
            <page-range>1463-1473</page-range>
            <pub-id pub-id-type="pmid">33387373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Sattawatthamrong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>NW</given-names>
              </name>
            </person-group>
            <article-title>Acute hyperglycaemia affects anorectal motor and sensory function in normal subjects.</article-title>
            <source>Gut</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>494</fpage>
            <page-range>494-9</page-range>
            <pub-id pub-id-type="pmid">9391248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Prior</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cheah</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Sensory and motor responses to rectal distention vary according to rate and pattern of balloon inflation.</article-title>
            <source>Gastroenterology</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>99</volume>
            <issue>4</issue>
            <fpage>1008</fpage>
            <page-range>1008-15</page-range>
            <pub-id pub-id-type="pmid">2394323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Broens</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vanbeckevoort</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bellon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Penninckx</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Combined radiologic and manometric study of rectal filling sensation.</article-title>
            <source>Dis Colon Rectum</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>1016</fpage>
            <page-range>1016-22</page-range>
            <pub-id pub-id-type="pmid">12195184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lotze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wietek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Birbaumer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ehrhardt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grodd</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Enck</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cerebral activation during anal and rectal stimulation.</article-title>
            <source>Neuroimage</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>1027</fpage>
            <page-range>1027-34</page-range>
            <pub-id pub-id-type="pmid">11697934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bharucha</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Pelvic floor: anatomy and function.</article-title>
            <source>Neurogastroenterol Motil</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>507</fpage>
            <page-range>507-19</page-range>
            <pub-id pub-id-type="pmid">16771766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>PORTER</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>A physiological study of the pelvic floor in rectal prolapse.</article-title>
            <source>Ann R Coll Surg Engl</source>
            <year>1962</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>379</fpage>
            <page-range>379-404</page-range>
            <pub-id pub-id-type="pmid">13985573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enck</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hinninghofen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Merletti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Azpiroz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The external anal sphincter and the role of surface electromyography.</article-title>
            <source>Neurogastroenterol Motil</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>17 Suppl 1</volume>
            <fpage>60</fpage>
            <page-range>60-7</page-range>
            <pub-id pub-id-type="pmid">15836456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shafik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>el-Sibai</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Rectal inhibition by inferior rectal nerve stimulation in dogs: recognition of a new reflex--the 'voluntary anorectal inhibition reflex'.</article-title>
            <source>Eur J Gastroenterol Hepatol</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>413</fpage>
            <page-range>413-8</page-range>
            <pub-id pub-id-type="pmid">11338072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshimura</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder.</article-title>
            <source>Prog Neurobiol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>583</fpage>
            <page-range>583-606</page-range>
            <pub-id pub-id-type="pmid">10221783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hassouna</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Neuromodulation reduces c-fos gene expression in spinalized rats: a double-blind randomized study.</article-title>
            <source>J Urol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>163</volume>
            <issue>6</issue>
            <fpage>1966</fpage>
            <page-range>1966-70</page-range>
            <pub-id pub-id-type="pmid">10799240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leng</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Chancellor</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>How sacral nerve stimulation neuromodulation works.</article-title>
            <source>Urol Clin North Am</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-8</page-range>
            <pub-id pub-id-type="pmid">15698871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aboseif</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamaddon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chalfin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mourad</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kaptein</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation in functional urinary retention: an effective way to restore voiding.</article-title>
            <source>BJU Int</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>90</volume>
            <issue>7</issue>
            <fpage>662</fpage>
            <page-range>662-5</page-range>
            <pub-id pub-id-type="pmid">12410743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Sacral Neuromodulation Improves Abnormal Prefrontal Brain Activity in Patients with Overactive Bladder: A Possible Central Mechanism.</article-title>
            <source>J Urol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>207</volume>
            <issue>6</issue>
            <fpage>1256</fpage>
            <page-range>1256-1267</page-range>
            <pub-id pub-id-type="pmid">35072489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janssen</surname>
                <given-names>PTJ</given-names>
              </name>
              <name>
                <surname>Komen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Melenhorst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bouvy</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Jahanshahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Temel</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Breukink</surname>
                <given-names>SO</given-names>
              </name>
            </person-group>
            <article-title>Sacral Neuromodulation for Fecal Incontinence: A Review of the Central Mechanisms of Action.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>51</volume>
            <issue>8</issue>
            <fpage>669</fpage>
            <page-range>669-676</page-range>
            <pub-id pub-id-type="pmid">28723864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gourcerol</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vitton</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Leroi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Michot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Abysique</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bouvier</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>How sacral nerve stimulation works in patients with faecal incontinence.</article-title>
            <source>Colorectal Dis</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>e203</fpage>
            <page-range>e203-11</page-range>
            <pub-id pub-id-type="pmid">21689312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duchalais</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Drissi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Delestre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wyart</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lehur</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Meurette</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Long-term results of sacral neuromodulation for the treatment of anorectal diseases.</article-title>
            <source>J Visc Surg</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>159</volume>
            <issue>6</issue>
            <fpage>463</fpage>
            <page-range>463-470</page-range>
            <pub-id pub-id-type="pmid">34736877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zillioux</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>955</fpage>
            <page-range>955-961</page-range>
            <pub-id pub-id-type="pmid">35238421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wald</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Management of Fecal Incontinence.</article-title>
            <source>Curr Gastroenterol Rep</source>
            <year>2018</year>
            <month>Mar</month>
            <day>26</day>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>9</fpage>
            <pub-id pub-id-type="pmid">29582182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erol</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Danacioglu</surname>
                <given-names>YO</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Current advances in neuromodulation techniques in urology practices: A review of literature.</article-title>
            <source>Turk J Urol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>375</fpage>
            <page-range>375-385</page-range>
            <pub-id pub-id-type="pmid">35118977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00160;lauf</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vobo&#x00159;il</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation for faecal incontinence - 10 years experience and long-term outcomes of a specialized centre.</article-title>
            <source>Rozhl Chir</source>
            <year>2021</year>
            <season>Winter</season>
            <volume>100</volume>
            <issue>10</issue>
            <fpage>475</fpage>
            <page-range>475-483</page-range>
            <pub-id pub-id-type="pmid">35021838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Is percutaneous tibial nerve stimulation (PTNS) effective for fecal incontinence (FI) in adults compared with sham electrical stimulation? A meta-analysis.</article-title>
            <source>Tech Coloproctol</source>
            <year>2024</year>
            <month>Feb</month>
            <day>24</day>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">38401006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bevan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Management of urinary incontinence in women: summary of updated NICE guidance.</article-title>
            <source>BMJ</source>
            <year>2013</year>
            <month>Sep</month>
            <day>10</day>
            <volume>347</volume>
            <fpage>f5170</fpage>
            <pub-id pub-id-type="pmid">24021756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Longhurst</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Sacral nerve stimulation for the management of voiding dysfunction.</article-title>
            <source>Rev Urol</source>
            <year>2000</year>
            <season>Winter</season>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-60</page-range>
            <pub-id pub-id-type="pmid">16985735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ginsberg</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Boone</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Gousse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Keays</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kennelly</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lemack</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Rovner</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Souter</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-up.</article-title>
            <source>J Urol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>206</volume>
            <issue>5</issue>
            <fpage>1106</fpage>
            <page-range>1106-1113</page-range>
            <pub-id pub-id-type="pmid">34495688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butrick</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Patient selection for sacral nerve stimulation.</article-title>
            <source>Int Urogynecol J</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>21 Suppl 2</volume>
            <fpage>S447</fpage>
            <page-range>S447-51</page-range>
            <pub-id pub-id-type="pmid">20972547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>W&#x000f6;llner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hampel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Surgery Illustrated &#x02013; surgical atlas sacral neuromodulation.</article-title>
            <source>BJU Int</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>146</fpage>
            <page-range>146-59</page-range>
            <pub-id pub-id-type="pmid">22691023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sayed</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chakravarthy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Amirdelfan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kalia</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Meacham</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shirvalkar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Falowski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hagedorn</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leever</surname>
                <given-names>J</given-names>
              </name>
              <collab>ASPN MRI Compatibility Working Group</collab>
              <name>
                <surname>Deer</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A Comprehensive Practice Guideline for Magnetic Resonance Imaging Compatibility in Implanted Neuromodulation Devices.</article-title>
            <source>Neuromodulation</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>893</fpage>
            <page-range>893-911</page-range>
            <pub-id pub-id-type="pmid">32809275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amundsen</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Jamison</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?</article-title>
            <source>Urology</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>746</fpage>
            <page-range>746-50</page-range>
            <pub-id pub-id-type="pmid">16230129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oerlemans</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>van Kerrebroeck</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Sacral nerve stimulation for neuromodulation of the lower urinary tract.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2008</year>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-33</page-range>
            <pub-id pub-id-type="pmid">17563110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zbar</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation and peripheral nerve stimulation in patients with anal incontinence: an overview of techniques, complications and troubleshooting.</article-title>
            <source>Gastroenterol Rep (Oxf)</source>
            <year>2014</year>
            <month>May</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>112</fpage>
            <page-range>112-20</page-range>
            <pub-id pub-id-type="pmid">24759349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liberman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ehlert</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Sacral Neuromodulation in Urological Practice.</article-title>
            <source>Urology</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>99</volume>
            <fpage>14</fpage>
            <page-range>14-22</page-range>
            <pub-id pub-id-type="pmid">27298200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hendrickson</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Amundsen</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation: troubleshooting needle placement.</article-title>
            <source>Int Urogynecol J</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>2549</fpage>
            <page-range>2549-2551</page-range>
            <pub-id pub-id-type="pmid">33416966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elias</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ganer Herman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Condrea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ginath</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Computed Tomography-Guided Placement of Sacral Electrodes.</article-title>
            <source>Isr Med Assoc J</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>12</issue>
            <fpage>773</fpage>
            <page-range>773-776</page-range>
            <pub-id pub-id-type="pmid">34954915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sampogna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montanari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Spinelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Computer-Assisted Lead Placement for Peripheral Nerve Evaluation Test in a Candidate for Sacral Neuromodulation.</article-title>
            <source>Int Neurourol J</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>382</fpage>
            <page-range>382-386</page-range>
            <pub-id pub-id-type="pmid">33401360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tilborghs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Wachter</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.</article-title>
            <source>Expert Rev Med Devices</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-187</page-range>
            <pub-id pub-id-type="pmid">35061951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tilborghs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van de Borne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vagan&#x000e9;e</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Win</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Wachter</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Influence of Electrode Configuration Changes on the Sensory and Motor Response During (Re)Programming in Sacral Neuromodulation.</article-title>
            <source>Neuromodulation</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>1173</fpage>
            <page-range>1173-1179</page-range>
            <pub-id pub-id-type="pmid">35088741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Kerrebroeck</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>van Voskuilen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Heesakkers</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lycklama &#x000e1; Nijholt</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Fall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gajewski</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Hassouna</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Cappellano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Elhilali</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Milam</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Dijkema</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>van den Hombergh</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>178</volume>
            <issue>5</issue>
            <fpage>2029</fpage>
            <page-range>2029-34</page-range>
            <pub-id pub-id-type="pmid">17869298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Preliminary analysis of stimulation parameters for sacral neuromodulation in different indications: A multi-center retrospective cohort study from China.</article-title>
            <source>Int J Surg</source>
            <year>2024</year>
            <month>Mar</month>
            <day>04</day>
            <pub-id pub-id-type="pmid">38445489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noblett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mangel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griebling</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Comiter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Culkin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zylstra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>199</volume>
            <issue>1</issue>
            <fpage>229</fpage>
            <page-range>229-236</page-range>
            <pub-id pub-id-type="pmid">28709886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coolen</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Groen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blok</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Electrical stimulation in the treatment of bladder dysfunction: technology update.</article-title>
            <source>Med Devices (Auckl)</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>337</fpage>
            <page-range>337-345</page-range>
            <pub-id pub-id-type="pmid">31572023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Troubleshooting Interstim Sacral Neuromodulation Generators to Recover Function.</article-title>
            <source>Curr Urol Rep</source>
            <year>2018</year>
            <month>Aug</month>
            <day>20</day>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>86</fpage>
            <pub-id pub-id-type="pmid">30128939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rueb</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fascelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Vasavada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rackley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The role of pulse width manipulation compared to program changes alone for unsatisfactory sacral neuromodulation therapy: A retrospective matched-cohort analysis.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>522</fpage>
            <page-range>522-528</page-range>
            <pub-id pub-id-type="pmid">33305838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xuan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bilateral electrical pudendal nerve stimulation as additional therapy for lower urinary tract dysfunction when stage II sacral neuromodulator fails: a case report.</article-title>
            <source>BMC Urol</source>
            <year>2021</year>
            <month>Mar</month>
            <day>10</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">33691669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Long-term efficacy of electrical pudendal nerve stimulation for urgency-frequency syndrome in women.</article-title>
            <source>Int Urogynecol J</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>397</fpage>
            <page-range>397-402</page-range>
            <pub-id pub-id-type="pmid">24091564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marinkovic</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>New technologies in the management of overactive bladder: current research and future prospects.</article-title>
            <source>Ther Adv Urol</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>11</volume>
            <fpage>1756287219844669</fpage>
            <pub-id pub-id-type="pmid">31040883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial.</article-title>
            <source>Urol J</source>
            <year>2014</year>
            <month>Sep</month>
            <day>06</day>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>1800</fpage>
            <page-range>1800-5</page-range>
            <pub-id pub-id-type="pmid">25194079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Carrico</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Perez-Marrero</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Wooldridge</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Macdiarmid</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.</article-title>
            <source>J Urol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>183</volume>
            <issue>4</issue>
            <fpage>1438</fpage>
            <page-range>1438-43</page-range>
            <pub-id pub-id-type="pmid">20171677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Carrico</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Wooldridge</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>MacDiarmid</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>189</volume>
            <issue>6</issue>
            <fpage>2194</fpage>
            <page-range>2194-201</page-range>
            <pub-id pub-id-type="pmid">23219541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tutolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ammirati</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Heesakkers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Rashid</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sievert</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Spinelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Novara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Van der Aa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Ridder</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature.</article-title>
            <source>Eur Urol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>406</fpage>
            <page-range>406-418</page-range>
            <pub-id pub-id-type="pmid">29336927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krhut</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rejchrt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Slovak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skugarevska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zvara</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Peroneal Electric Transcutaneous NeuroModulation (eTNM<sup>&#x000ae;</sup>): A Novel Method for the Treatment of the Overactive Bladder.</article-title>
            <source>J Healthc Eng</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>4016346</fpage>
            <pub-id pub-id-type="pmid">34659685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goudelocke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sobol</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Poulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Enemchukwu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zaslau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dhir</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A Multicenter Study Evaluating the FREquency of Use and Efficacy of a Novel Closed-Loop Wearable Tibial Neuromodulation System for Overactive Bladder and Urgency Urinary Incontinence (FREEOAB).</article-title>
            <source>Urology</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>183</volume>
            <fpage>63</fpage>
            <page-range>63-69</page-range>
            <pub-id pub-id-type="pmid">37944596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amundsen</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Komesu</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Chermansky</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Honeycutt</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Vasavada</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Harvie</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>D</given-names>
              </name>
              <collab>Pelvic Floor Disorders Network</collab>
            </person-group>
            <article-title>Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.</article-title>
            <source>Eur Urol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-73</page-range>
            <pub-id pub-id-type="pmid">29482936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tincello</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Kenyon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Mayne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Toozs-Hobson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Slack</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).</article-title>
            <source>Eur Urol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>507</fpage>
            <page-range>507-14</page-range>
            <pub-id pub-id-type="pmid">22236796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rizzolo</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin as a treatment for refractory overactive bladder.</article-title>
            <source>JAAPA</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">26818640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tay</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Harry</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Malde</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahai</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder.</article-title>
            <source>Urology</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>149</volume>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">33227305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paszkiewicz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hinkel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Oleson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Sacral nerve stimulation in patients with chronic intractable pelvic pain.</article-title>
            <source>J Urol</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>166</volume>
            <issue>5</issue>
            <fpage>1742</fpage>
            <page-range>1742-5</page-range>
            <pub-id pub-id-type="pmid">11586214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laviana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jellison</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome.</article-title>
            <source>Neurosurg Clin N Am</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-46</page-range>
            <pub-id pub-id-type="pmid">24262898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sievert</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Amend</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Toomey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Badke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaps</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Stenzl</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury.</article-title>
            <source>Ann Neurol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-84</page-range>
            <pub-id pub-id-type="pmid">20186953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gad</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Kreydin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Latack</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Edgerton</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Non-invasive Neuromodulation of Spinal Cord Restores Lower Urinary Tract Function After Paralysis.</article-title>
            <source>Front Neurosci</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>432</fpage>
            <pub-id pub-id-type="pmid">30008661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keller</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Patras</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hutu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Roider</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sievert</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Aigner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Janetschek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lusuardi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Early sacral neuromodulation ameliorates urinary bladder function and structure in complete spinal cord injury minipigs.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>586</fpage>
            <page-range>586-593</page-range>
            <pub-id pub-id-type="pmid">31868966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127382.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Redshaw</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lenherr</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Stoffel</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Rosenbluth</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Presson</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>JB</given-names>
              </name>
              <collab>Neurogenic Bladder Research Group (NBRG.org)</collab>
            </person-group>
            <article-title>Protocol for a randomized clinical trial investigating early sacral nerve stimulation as an adjunct to standard neurogenic bladder management following acute spinal cord injury.</article-title>
            <source>BMC Urol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>29</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <pub-id pub-id-type="pmid">30157824</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
